Genomic analysis of circulating tumor DNA (ctDNA) from patients with HR+, HER2-mutant metastatic breast cancer (MBC) enrolled in SUMMIT: mechanisms of acquired resistance to neratinib plus fulvestrant plus trastuzumab (N plus F plus T)

被引：0
|
作者：
Ma, Cynthia
Waisman, James
Brufsky, Adam M.
Yang, Eddy S.
Wildiers, Hans
Crown, John P.
Piha-Paul, Sarina A.
Suga, Jennifer M.
Garcia-Saenz, Jose Angel
Gambardella, Valentina
Guerrero, Angel
Stemmer, Salomon
Bose, Ron
Novara-Demgen, Tonya
DiPrimeo, Daniel
Eli, Lisa D.
Jhaveri, Komal
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-PD17-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD17-01
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Post progression treatments after endocrine therapy (ET) plus palbociclib in patients with HR+/HER2-metastatic breast cancer (MBC): A prospective, real-world study
    Palumbo, R.
    Saltalamacchia, G.
    Quaquarini, E.
    Tagliaferri, B.
    Teragni, C. M.
    Barletta, C.
    Frascaroli, M.
    Biscaldi, E.
    Malovini, A.
    Locati, L. D.
    Sottotetti, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S372 - S372
  • [42] Utility of lymphocyte-monocyte ratio (LMr) for predicting progression free survival (PFS) in patients with HR+/HER2-metastatic breast cancer (MBC) treated with palbocilcib plus fulvestrant as first-line therapy
    Raimondi, L.
    Pietranera, M.
    Rossi, L.
    Di Rocco, A.
    Gozzi, E.
    Cimino, G.
    Spinelli, G. P.
    ANNALS OF ONCOLOGY, 2020, 31 : S363 - S363
  • [43] monarcHER: A phase 2 randomized open-label study of abemaciclib plus trastuzumab (T) with or without fulvestrant (F) compared to standard-of-care chemotherapy of physician's choice plus T in women with HR +, HER2+advanced breast cancer
    Tolaney, S. M.
    Bourayou, N.
    Goel, S.
    Forrester, T.
    Andre, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [44] MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast Cancer
    Neven, Patrick
    Johnston, Stephen R. D.
    Toi, Masakazu
    Sohn, Joohyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga
    Okera, Meena
    Masuda, Norikazu
    Kaufman, Peter A.
    Koh, Han
    Grischke, Eva-Maria
    Conte, PierFranco
    Lu, Yi
    Haddad, Nadine
    Hurt, Karla C.
    Llombart-Cussac, Antonio
    Sledge, George W.
    CLINICAL CANCER RESEARCH, 2021, 27 (21) : 5801 - 5809
  • [45] MONARCH 2: Subgroup analysis of patients receiving abemaciclib plus fulvestrant as first- and second-line therapy for HR+, HER2-advanced breast cancer.
    Neven, Patrick
    Johnston, Stephen R. D.
    Toi, Masakazu
    Sohn, Joohyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga Nikolaevna
    Okera, Meena
    Masuda, Norikazu
    Koh, Han A.
    Grischke, Eva-Maria
    Conte, Pier Franco
    Lu, Yi
    Haddad, Nadine
    Hurt, Karla
    Kaufman, Peter A.
    Llombart-Cussac, Antonio
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) plus trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Modi, S.
    Sugarman, S.
    Stopeck, A.
    Linden, H.
    Ma, W.
    Kersey, K.
    Johnson, R. G.
    Rosen, N.
    Hannah, A. L.
    Hudis, C. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) plus Ctx versus trastuzumab (T) plus Ctx in patients (pts) with pretreated HER2+metastatic (met) breast cancer (MBC).
    Escriva, Santiago
    Im, Seock-Ah
    Cardoso, Fatima
    Cortes, Javier
    Curigliano, Giuseppe
    Gradishar, William John
    Pegram, Mark D.
    Wright, Gail Lynn Shaw
    Levy, Christelle
    De laurentiis, Michelino
    Ferrero, Jean-Marc
    Bahadur, Shakeela Wazeen
    Kim, Sung-Bae
    Petrakova, Katarina
    Riseberg, David A.
    Yardley, Denise A.
    Edlich, Sutton
    Hong, Sam
    Rock, Edwin P.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] A Phase Ib Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients with Locally Advanced or Metastatic HR+/HER2-Breast Cancer Who Failed Standard of Care Therapies
    Xu, Binghe
    Zhang, Pin
    Sun, Tao
    Wang, Ying
    Tong, Zhongsheng
    Phadke, Sneha
    Feinstein, Trevor
    Guo, Pengfei
    Qu, Jing
    Wang, Xiaoyu
    CANCER RESEARCH, 2024, 84 (09)
  • [49] Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)
    Turner, Nicolas
    Jhaveri, Komal
    Kalinsky, Kevin
    Loibl, Sibylle
    Loi, Sherene
    Im, Seock-Ah
    Saura, Cristina
    Schmid, Peter
    Schutzman, Jennifer L.
    Stout, Thomas J.
    Lei, Guiyuan
    Hutchinson, Katherine E.
    Thanopoulou, Eirini
    Juric, Dejan
    CANCER RESEARCH, 2021, 81 (04)
  • [50] POSEIDON randomized phase II trial: Tamoxifen (TAM) plus taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2-metastatic breast cancer (MBC)
    Oliveira, M.
    Baird, R. D.
    Voorthuis, R. A. B.
    De Boo, L.
    van Rossum, A. G. J.
    Cubells, L. Garrigos
    Munoz, S.
    Lopez-Garcia, D.
    Manich, C. Saura
    Schrier, M.
    Mandjes, I.
    Sikorska, K.
    Schot, M.
    Kateb, A.
    Mather, C.
    Beelen, K.
    Cortes, J.
    Caldas, C.
    Linn, S. C.
    ANNALS OF ONCOLOGY, 2021, 32 : S1291 - S1292
12345